A Phase 1 interventional study of LY3841136 and LY3841136-Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing eloralintide in Obesity — 13 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.
Among the 22 studies testing eloralintide in Obesity, this one is the 16th largest by enrollment, is one of 4 that started in 2024, is one of 9 in phase 1, and was the 4th registered.
11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →13 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in Germany, Sweden
Ages 18–70 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–75
Eli Lilly and Company · Sites in United States, Australia, Brazil and 8 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2024.
This study's enrollment of 128 is above the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 315 across the 22 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 30 open now, 54 under way, 30 of them phase 3. Of 62 finished, 29 (47%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 85th largest by enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, and was the 47th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
7 of the studies testing eloralintide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
| NCT07808060Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight | 2027-06 |
| NCT07765511Eli Lilly and CompanyA Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes | 2027-06 |
| NCT07665879Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies testing eloralintide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY3841136 administered subcutaneously (SC)
Drug: LY3841136
Placebo administered SC
Drug: LY3841136-Placebo
Tirzepatide administered SC along with volume-matched LY3841136-Placebo administered SC
Drug: LY3841136-Placebo · Drug: Tirzepatide
LY3841136 administered SC along with volume-matched Tirzepatide-Placebo administered SC
Drug: LY3841136 · Drug: Tirzepatide-Placebo
LY3841136 administered SC along with Tirzepatide administered SC
Drug: LY3841136 · Drug: Tirzepatide
Volume-matched LY3841136-Placebo administered SC along with volume-matched Tirzepatide-Placebo administered SC
Drug: LY3841136-Placebo · Drug: Tirzepatide-Placebo
Administered SC
Administered SC
Administered SC
Administered SC
Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 22
Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 34
Part A Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136
PK: AUC of LY3841136 alone
Time frame: Predose through Week 22
Part A PK: Maximum Observed Concentration (Cmax) of LY3841136
PK: Cmax of LY3841136 alone
Time frame: Predose through Week 22
Part A Pharmacodynamics (PD): Change From Baseline in Body Weight at Week 12
PD: Change from baseline in body weight
Time frame: Baseline through Week 12
Part B PK: AUC of LY3841136 in Combination with Tirzepatide
PK: AUC of LY3841136 in combination with tirzepatide
Time frame: Predose through Week 34
Part B PK: Cmax of LY3841136 in Combination with Tirzepatide
PK: Cmax of LY3841136 in combination with tirzepatide
Time frame: Predose through Week 34
Part B PD: Change From Baseline in Body Weight at Week 24
PD: Change from baseline in body weight
Time frame: Baseline through Week 24
Plan to share: No
Ran from Apr 2024 to primary completion in Nov 2025, 19 months.
Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 19 months is above that.
Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eloralintide